Dendreon Corporation (NASDAQ: DNDN) has announced that its pivotal Phase 3 IMPACT study of PROVENGE in men with advanced prostate cancer data. While the data is incomplete, Dendreon said that the IMPACT study met…
About two years ago, GE (GE) began to talk about its “green” initiative and how important it was that businesses and governments begin to work on sustainable energy solutions to save the environment. Of…
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is taking it right on the chin this morning. The company announced that it has received a “refuse to file letter” from the FDA regarding its New Drug Application…
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) is getting shelled this morning. The company released “positive study data” this morning on trials for its obesity treatment Lorcaserin. But the real issue around the results is that…
Osiris Therapeutics, Inc. (NASDAQ: OSIR) is seeing its stock getting pounded this morning. The company announced that it was ending enrollment at 210 patients in its Phase III trial evaluating its Prochymal for Crohn’s…
If the rumor mill has any truth to it, then Allergan Inc. (NYSE: GSK) may by the next biotech takeover target. There is roughly $150 billion in new equity investor capital that can be…
The hope for a higher Genentech Inc. (NYSE: DNA) buyout price is getting smaller and smaller. After the companies agreed to a $95.00 per share merger, this was already assumed as the nearly certain…
Gilead Sciences, Inc. (Nasdaq: GILD) has agreed to buy CV Therapeutics, Inc. (Nasdaq: CVTX) for $20.00 per share in cash.
Pfizer Inc. (NYSE: PFE) is stopping its Phase III clinical trial of Sutent early. This is generally a scare over adverse events, but not in this case. Sutent apparently has shown such a significant…
Before Roche decided to try to buy the 44% of biotech company Genentech (DNA) that it did not already own the smaller firm traded at $75. Roche offered just over $86 a share. Genentech…
Pfizer Inc. (NYSE: PFE) just got its long-term ratings downgraded by Moody’s. It is amazing that bond ratings agencies still get to operate in a business as usual manner, but they do. Long gone…
The AMA, the federal government, and most insurance companies and HMOs have been arguing that storing and updating medical records digitally is much more efficient than having them on paper. The argument is compelling.…
Merck (MRK) is merging with Schering-Plough (SGP) in a deal that the companies say is worth $41.1 billion. In reality, Merck is making an acquisition. Its shares will be the currency to compete the…
Roche has apparently capitulated in its fight to take over Genentech Inc. (NYSE: DNA). Its cancer franchise and its pipeline, along with a shareholder proxy fight, finally made Roche tip its hand. The company’s…
We are seeing unusual trading activity so far this morning in shares of Dendreon Corp. (NASDAQ: DNDN), Genentech, Inc. (NYSE: DNA), Genzyme Corp. (NASDAQ: GENZ), and PDL BioPharma, Inc. (Nasdaq: PDLI).